Search Results
Keyword:radiopharmaceutical
Aktis Oncology Expands Clinical Enrollment for Actinium-Based Radiopharmaceuticals
Recently, Aktis Oncology of the United States disclosed the latest expanded enrollment arrangements for two clinical studies of innovative targeted radiopharmaceuticals based on Actinium-225. While continuing to advance the established dose-escalation trials, the company has added dedicated supplementary enrollment cohorts at selected dose levels for AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3, respectively, aiming to comprehensively observe the safety, tolerability, and preliminary antitumor activity of the drugs in specific patient populations, and to accumulate detailed data for subsequent large-scale clinical development. In terms of specific clinical progress, the Nectin-4-targeting AKY-...
2026-11-16
Aktis Oncology Advances Actinium-Based Radiopharmaceutical Expansion with Additional Enrollment and In-House Supply
Recently, Aktis Oncology, an innovative company focused on developing targeted radiopharmaceuticals, officially disclosed the latest enrollment arrangements for two innovative targeted radiopharmaceutical studies based on Actinium-225. While continuing to advance dose-escalation trials, the company has substantially expanded supplemental patient enrollment for its two core pipeline candidates, AKY-1189 and AKY-2519, at selected dose levels, aiming to comprehensively observe and characterize their safety, tolerability, and preliminary antitumor activity, thereby accumulating detailed data support for subsequent pivotal clinical development. Among them, AKY-1189, which targets Nectin-4, is currently in the NECTINIUM-2 Phase Ⱬb...
2026-11-13
Exploration of the Application of the Performance Excellence Model in Program Management of Isotope Pharmaceutical Center Projects
Recently, China Isotope & Radiation Corporation, a leading enterprise in the domestic radiopharmaceutical industry, focusing on practicing the "Six Controls and Seven Zeros" and the concept of refined management throughout the entire engineering construction process, conducted an in-depth review of the lessons learned from 30 completed and operational projects, and systematically established and comprehensively promoted a performance excellence-oriented management and control system for the isotope pharmaceutical center project portfolio. This innovative practice has effectively addressed the management and control pain points of pharmaceutical center projects being "small, scattered, and remote," and has pressed the "accelerator" for the high-quality deployment of the national radiopharmaceutical supply network. With the accelerating pace of nuclear medicine innovation and capacity upgrading since the 14th Five-Year Plan period, China Isotope & Radiation Corporation has cumulatively deployed 37 pharmaceutical center projects, with business coverage spanning...
2026-11-13
Oman Launches First Local Production Project for Diagnostic and Therapeutic Radiopharmaceuticals
Recently, Oman officially launched its first local production project for diagnostic and therapeutic radiopharmaceuticals. Named "Nucleus Oman," the project has a planned total investment of 6.5 million Omani Rials (approximately USD 17 million) and is being jointly advanced by the Oman Investment Authority (OIA) and Saudi Arabia's Oryx Isotopes Industry Company, with strong coordination and support from Oman's Ministry of Health and Ministry of Finance. The project adopts an overall public-private partnership (PPP) model. The joint venture entity established by the Oman Investment Authority and Oryx Isotopes Industry Company will, in accordance with a long-term agreement formally signed with Oman's Ministry of Health...
2026-11-10
US Company Publishes Long-Term Safety Study of Targeted Radiopharmaceutical for Leukemia
Recently, a new American Society of Hematology (ASH) conference abstract has been developed from the long-term safety and tolerability study of Actimab-A combined with CLAG-M intensive salvage chemotherapy, focusing on the recovery of patients with relapsed or refractory acute myeloid leukemia after treatment. This progress extends the research focus from prior antitumor activity to long-term follow-up, supplementing data for continued development of the combination regimen. Actimab-A is an investigational targeted α therapy developed by Actinium Pharmaceuticals, composed of the antibody lintuzumab conjugated with actinium-225. This abstract involves follow-up of patients in a Phase I study who survived at least three months after treatment, with emphasis on analyzing blood cell count recovery and potential delayed renal and hepatic toxicity, in order to more comprehensively evaluate the safety profile after intensive treatment.
2026-11-05
Australian Company Finalizes Phase III Protocol for Brain Metastasis Imaging Radiopharmaceutical
Recently, Radiopharm Theranostics announced that it has received the final meeting minutes from the FDA End-of-Phase 2 meeting, during which both parties reached agreement on the design of the pivotal Phase III imaging trial for RAD101, advancing registration development preparations for this investigational radiopharmaceutical imaging agent. The study is planned as a single-arm, multicenter Phase III trial designed to enroll approximately 280 patients with previously irradiated brain metastases of indeterminate nature. The co-primary endpoints are the sensitivity and specificity of RAD101 PET relative to an established reference standard. RAD101 is labeled with Fluorine-18, and its development goal is to help identify brain metastasis lesions and improve the differentiation between tumor recurrence and treatment-related changes. Si...
2026-11-04
CNNC Atom High-Tech Sodium Iodide Capsules Supplied Directly to Macao for the First Time
Recently, sodium iodide [¹³¹I] capsules independently developed and produced by Atom High-Tech Co., Ltd., a subsidiary of China Isotope & Radiation Corporation under CNNC, successfully arrived at clinical frontlines in Macao, achieving the first stable supply of domestically produced sodium iodide [¹³¹I] capsules to Macao and completely filling the previous gap in Macao's lack of this clinical diagnostic and therapeutic service. It is understood that sodium iodide [¹³¹I] capsules are core radiopharmaceuticals widely used clinically for the diagnosis and treatment of thyroid diseases. Previously, Atom High-Tech had successfully achieved routine supply of short-half-life radiopharmaceuticals to Macao; the successful launch of this new product will strongly support Macao medical institutions in carrying out systematic radionuclide therapy and effectively reduce the burden of cross-border medical treatment on local patients.
2026-11-02
CNNC Hosts the 6th Radiopharmaceutical and Radionuclide Production Worker Vocational Skills Competition, Leveraging Shared Laboratories to Deepen Skilled Talent Cultivation
The 2026 6th CNNC Radiopharmaceutical and Radionuclide Production Worker Vocational Skills Competition, themed "Forging Craftsmanship with Nuclear Power, Winning the Future with Skills," was successfully held from October 20 to 24 at the Nuclear and Radiation Safety Center of the Ministry of Ecology and Environment. The competition was hosted by CNNC and organized by China Isotope & Radiation Corporation, and is a key practical measure for CNNC and the Nuclear and Radiation Safety Center to deepen strategic coordination and advance the construction of shared laboratories. The two sides closely focused on research directions including radiation environmental monitoring, nuclide analysis, and precise sample testing, promoting the co-construction and sharing of instruments and equipment, reference materials, methodology systems, and data platforms. A total of 16 units and 3...
2026-10-25
Southwest Supervision Station of the National Nuclear Safety Administration Conducts Demonstrative Supervision of Radiopharmaceuticals
Recently, the Southwest Nuclear and Radiation Safety Supervision Station of the Ministry of Ecology and Environment (National Nuclear Safety Administration), together with the Department of Radiation Source Safety Supervision, the Nuclear and Radiation Safety Center of the Ministry of Ecology and Environment, and Chengdu University of Technology, organized representatives of enterprises in its jurisdiction to conduct demonstrative supervision of radiopharmaceutical (medical isotope) production. This initiative aims to serve the national "Medium- and Long-Term Development Plan for Medical Isotopes (2021–2035)" and comprehensively enhance the radiation safety management level of the nuclear medical industry in the Southwest region. It is reported that this supervision activity practiced the concept of research-based supervision. In response to the characteristics of the Southwest region—where R&D, pilot testing, and large-scale production proceed in parallel, and the safety risks of unsealed radioactive materials are complex—the activity involved pre-arranging production processes...
2026-10-22
The 18th National Symposium on Radiopharmaceuticals and Labeled Compounds Held in Chongqing, Focusing on Alpha Nuclide Targeting and Theranostics
The 18th National Symposium on Radiopharmaceuticals and Labeled Compounds was held on October 10-11 at the Chongqing Science Hall. The conference was co-hosted by the China Isotope & Radiation Corporation Research Institute and the IAEA Collaborating Centre for Radiopharmaceuticals and Radioactive Sources, co-organized by the Nuclear Medicine Branch of the Chinese Medical Association, the Isotope Branch of the Chinese Nuclear Society, the Radiopharmaceuticals Branch of the Chinese Nuclear Society, and the Nuclear Chemistry and Radiochemistry Branch of the Chinese Nuclear Society, and undertaken by China Isotope & Radiation Corporation and the Chongqing Nuclear Society. More than 400 experts, scholars, clinicians and...
2026-10-12
GE HealthCare Plans $945 Million All-Cash Acquisition of Sofie Biosciences: Full-Scale Positioning in the "Final Mile" Delivery of Positron Radiopharmaceuticals and CDMO Capacity
GE HealthCare, the Chicago-based medical imaging and radiodiagnostics giant, has announced that it has entered into a definitive acquisition agreement to acquire radiopharmaceutical company Sofie Biosciences in an all-cash deal valued at $945 million from private equity firm Trilantic North America. The transaction is expected to complete all regulatory approvals and closing procedures by July 2027, and is expected to be accretive to GE HealthCare's revenue growth and adjusted earnings in the first full fiscal year following closing. Founded in 2008 and headquartered in Dulles, Virginia, Sofie Biosciences has built a broad radiopharmaceutical production and distribution network across the United States...
2026-10-08
GE HealthCare Plans $1 Billion Acquisition of Radiopharmaceutical Company Sofie Biosciences
According to reports, healthcare giant GE HealthCare is in talks to acquire radiopharmaceutical company Sofie Biosciences for $1 billion. It is understood that this acquisition will be another major business move for GE HealthCare since its spin-off from General Electric Company in 2023. Previously, the company reached an agreement in March of this year to acquire software company Intelerad for $2.3 billion, aiming to enhance its cloud-based enterprise imaging service capabilities. Sofie Biosciences was founded in 2008 and is headquartered in Dulles, Virginia. The company has a well-established radiopharmaceutical production and distribution network and provides contract manufacturing services. In addition, Sofie Biosci...
2026-09-15
Canada Supports IAEA "Rays of Hope" Initiative for the First Time, Will Provide Medical Isotope Training for Latin America
The Canadian Nuclear Isotope Council (CNIC) announced on September 10 that Canada has for the first time formally provided support to the International Atomic Energy Agency (IAEA) Rays of Hope initiative, and will help enhance cancer diagnosis and treatment capacity in Latin America through training in the production of medical radioisotopes and radiopharmaceuticals. The Rays of Hope initiative aims to expand access to cancer treatment and radiotherapy infrastructure in low- and middle-income countries. Under the arrangement, from November 8 to 14, 26 relevant sector leaders from Argentina, Brazil, Chile and Mexico will travel to Ontario, Canada, to participate in a training program jointly organized by Bruce Power and McMaster University. The training will focus on medical isotopes...
2026-09-11
South Korea's First Animal Radiopharmaceutical Approved for the Treatment of Feline Hyperthyroidism
The Korea Atomic Energy Research Institute announced on September 10 that Thyrokitty Injection (I-131), a radiopharmaceutical for the treatment of feline hyperthyroidism developed by the research team led by Dr. Lim Jae-cheong, has obtained an animal drug manufacturing license issued by the Animal and Plant Quarantine Agency of South Korea. This is South Korea's first animal radiopharmaceutical to receive final product approval, marking the transition of related technologies that had previously been mainly at the R&D stage into clinical therapeutic application for pets. Feline hyperthyroidism is a relatively common endocrine disease in older cats, mainly characterized by excessive secretion of thyroid hormones. According to reports, approximately 10% of cats aged 10 and above may suffer from this disease. Traditional treatment methods typically require...
2026-09-10
ITM and SpiroChem Announce Strategic Collaboration to Advance Novel Radiopharmaceutical Development
Garching/Munich, Germany and Basel, Switzerland, September 8, 2026 – Radiopharmaceutical biotechnology company ITM Isotope Technologies Munich SE and Swiss collaborative research organization SpiroChem AG today announced a strategic drug discovery partnership focused on a novel radiopharmaceutical candidate within ITM's pipeline. The specific target and financial terms of the collaboration were not disclosed. Under the agreement, the parties will combine their respective capabilities to advance candidate discovery and optimization. SpiroChem will leverage its drug discovery platform, macrocycle library, and screening engine to lead hit identification and optimization, while ITM will provide...
2026-09-09